MTOR and neoplasm: To this regard, modulating systemic glucose via sodium-glucose co-transporter 2 (SGLT-2) inhibitor drugs, which target the mammalian target of rapamycin (mTOR) signalling pathway, reduced tumour cell proliferation and induction of breast cell apoptosis (118).